Drug maker Merck & Co. is facing criticism that it is overpaying for its planned $8.4 billion purchase of antibiotics specialistCubist Pharmaceuticals Inc., in light of a court ruling issued hours after the deal was announced Monday that could dampen the sales potential for Cubist’s top-selling drug.. Leerink Partners analyst Seamus Fernandez said the purchase price appeared to be about $2 billion to $3 billion too high, based on reduced sales expectations for the Cubist drug, the antibiotic Cubicin.